SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJudges Scientific Regulatory News (JDG)

Share Price Information for Judges Scientific (JDG)

Share Price is delayed by 15 minutes
Get Live Data
4,670.00    220.00 (4.94%)
Bid:
4,620.00
Ask:
4,720.00
Spread: 100.00 (2.165%)
Market Cap: £311.05m
JDG Live PriceLast checked at - London Stock Exchange

Intraday Judges Scientific Share Chart

Trading Statement

18 Jul 2013 07:00

RNS Number : 5740J
Judges Scientific PLC
18 July 2013
Β 

Β 

Β 

Judges Scientific plc

Trading Statement

Β 

18 July 2013

Β 

Judges Scientific plc ('Judges Scientific', the 'Company' or the 'Group')

Β 

Trading Update

Β 

The Directors of Judges Scientific, the parent company of a group specialising in the design, manufacture and sale of scientific instruments, are pleased to update shareholders and the market with regard to the Group's trading performance during the first half of the current financial year.

The interim Income Statement for the six months to 30 June 2013 will not include any results from Scientifica Ltd ("Scientifica"), which was acquired on 26 June 2013 and represents the Group's largest acquisition to date. The interim Balance Sheet will reflect the acquisition.

The Group's businesses delivered a satisfactory trading performance during the period. The interim results, scheduled to be announced in September, are expected to show revenue growth of 14% compared with the six months to 30Β June 2012; this includes organic growth of 4.4% and the effect of a full six-month contribution from Global Digital Systems ("GDS") and KE Developments ("KED") compared with a four-month contribution in the first half of 2012. The Board anticipates that interim profits before exceptional items will reflect this satisfactory sales performance. Adjusted basic earnings per share are also expected to advance, despite the 20% dilution resulting from the May 2012 share issue and the conversion of most of the convertible redeemable shares in the second half of 2012.

Order intake during the six-month period showed only slight organic growth, with a strong first quarter being followed by a weak second quarter. Had GDS and Scientifica been part of Judges throughout the first-half periods of both 2012 and 2013, the Group as presently constituted would have shown 13% growth in order intake for the period. The order book at 30 June 2013 (excluding Scientifica) represented 10.6 weeks of sales, somewhat ahead of the 10-week level at 30 June 2012.

Operating cash flow was healthy during the period. The interim Balance Sheet will show the impact of the Scientifica acquisition and of the majority of the building cost of the Stonecross property; net debt still rests at a prudent multiple of operating profit.

Several other companies in our sector have recently reported challenging conditions and our own markets have not been uniformly positive. However, the resilience of Judges' diversified business activities has enabled the Company to continue to pursue its objectives in a lacklustre environment.

Β 

Β 

For further information please contact:

Judges Scientific Plc

David Cicurel, CEO

Tel: 01342 323 600

Β 

Shore Capital (Nominated Adviser & Broker)

Pascal Keane

Edward Mansfield

Tel: 020 7408 4090

Β 

Cardew Group (Financial Public Relations)

Melvyn Marckus

Tel: 020 7930 0777 or 07775 896 491

Β 

Websites:

Judges Scientific: www.judges.uk.comΒ 

Scientifica: http: www.scientifica.uk.com

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTDMGMNVNNGFZM
Date   Source Headline
16th Sep 20147:00 amRNSNotice of Results
10th Sep 20147:00 amRNSDirector/PDMR Shareholding
8th Aug 20142:29 pmRNSDirector/PDMR Shareholding
22nd Jul 20147:00 amRNSDirector/PDMR Shareholding
18th Jul 20143:14 pmRNSHolding(s) in Company
17th Jul 20147:00 amRNSTrading Statement
9th Jul 20145:24 pmRNSDirector/PDMR Shareholding
6th Jun 20143:52 pmRNSDirector/PDMR Shareholding
5th Jun 201412:03 pmRNSIssue of Equity
3rd Jun 20144:15 pmRNSDirector/PDMR Shareholding
23rd May 20143:20 pmRNSExercise of options
22nd May 20147:00 amRNSPayment of deferred consideration for Scientifica
19th May 20143:08 pmRNSExercise of options
12th May 20141:54 pmRNSDirector/PDMR Shareholding
24th Apr 20145:30 pmRNSExercise of Options
10th Apr 201412:01 pmRNSExercise of options
8th Apr 20146:15 pmRNSDirector/PDMR Shareholding
4th Apr 20142:28 pmRNSExercise of Options
28th Mar 20147:00 amRNSFinal Results
10th Mar 201410:00 amRNSNotice of Results
10th Mar 20148:51 amRNSDirector/PDMR Shareholding
7th Feb 20142:53 pmRNSDirector/PDMR Shareholding
24th Jan 20147:00 amRNSTrading Statement
22nd Jan 20142:01 pmRNSExercise of Options
13th Jan 20141:40 pmRNSHolding(s) in Company
10th Jan 20146:00 pmRNSHolding(s) in Company
9th Jan 20144:34 pmRNSDirector/PDMR Shareholding
13th Dec 201310:31 amRNSIssue of Equity
10th Dec 20138:39 amRNSDirector/PDMR Shareholding
4th Dec 20134:06 pmRNSIssue of Equity
26th Nov 20133:31 pmRNSDirector/PDMR Shareholding
20th Nov 20137:00 amRNSTrading Statement
7th Nov 20132:04 pmRNSDirector/PDMR Shareholding
25th Oct 20135:24 pmRNSHolding(s) in Company
25th Oct 20134:19 pmRNSDirector/PDMR Shareholding
21st Oct 20137:00 amRNSPlacing to raise GBP8.125 million
9th Oct 20131:25 pmRNSDirector/PDMR Shareholding
2nd Oct 20135:47 pmRNSHolding(s) in Company
26th Sep 20137:00 amRNSHalf Yearly Report
17th Sep 20134:17 pmRNSNotice of Results
9th Sep 20134:15 pmRNSDirector/PDMR Shareholding
13th Aug 201312:48 pmRNSHolding(s) in Company
6th Aug 20134:33 pmRNSDirector/PDMR Shareholding
18th Jul 20132:04 pmRNSDirector/PDMR Shareholding
18th Jul 20137:00 amRNSTrading Statement
15th Jul 20134:59 pmRNSExercise of Options
10th Jul 20131:27 pmRNSExercise of options
9th Jul 20137:00 amRNSDirector/PDMR Shareholding and Issue of Equity
27th Jun 20134:52 pmRNSHolding(s) in Company
27th Jun 20137:00 amRNSAcquisition and Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.